NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
7 Hills Pharma, LLC
Eikon Therapeutics
Novartis
GlaxoSmithKline
Radiopharm Theranostics, Ltd
Replimune Inc.
GlaxoSmithKline